Tag: Richard R.P. Warner
December Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community
Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City on Sunday, December 6, 2015. This special program was initiated and is sponsored by the Big Apple…
READ MORECarcinoid Cancer Foundation Announces New Video Series
In recognition and support of Worldwide NET Cancer Awareness Day, the Carcinoid Cancer Foundation is pleased to announce a new video series that will begin in 2012. This series, made possible by the generosity of Kim, Heather and Lauren Simpson and other…
READ MORERadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MOREWebMD Articles Raise Awareness about Carcinoid Cancer
Understanding carcinoid tumors, carcinoid syndrome, and treatments for carcinoid when surgery is not an option are the focus of three feature articles by Ellen Greenlaw on WebMD.com this month. For these articles, Ms. Greenlaw sought the expertise…
READ MORECarcinoid Cancer Foundation Thanks Steve Jobs for Bringing about Greater Awareness of Neuroendocrine Cancers
Since the announcement was made earlier this month that Apple’s CEO Steve Jobs would be taking a medical leave of absence there has been significant media coverage about pancreatic neuroendocrine tumors, NET cancer, and carcinoid. Although…
READ MOREFDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MOREStudy to Evaluate Families with History of Carcinoid Cancer
The Natural History of Familial Carcinoid Tumor is recruiting participants who are interested in being part of a study that will “evaluate families with a history of carcinoid cancer to determine ways to improve early detection and to find the gene that…
READ MORECarcinoid & Neuroendocrine Cancer Conference Presented by CCAN Now Online
If you missed the carcinoid and NET conference presented by the Carcinoid Cancer Awareness Network in November, you can now view it online. And if you want to hear some great presentations again, click here.
The guest speakers and their presentations …
READ MOREClinical Trial Recruiting Neuroendocrine Tumor Patients with Pheochromocytoma or Paraganglioma
Neuroendocrine tumor patients with malignant pheochromocytoma or paraganglioma are being sought for a multi-center clinical trial conducted by Molecular Insight Pharmaceuticals, Inc. In the New York area, one of the clinical trial sites is the Mount…
READ MORECarcinoid Cancer and Neuroendocrine Tumor Patients: Where Do I Start?
There are so many questions when you are newly diagnosed with carcinoid cancer or another neuroendocrine tumor. Where do I start to learn more about these rare cancers? When patients or their families call the support and information line at the Carcinoid…
READ MORE